Mobilion Systems
MOBILion Systems develops and commercializes the MOBIE® High-Resolution Ion Mobility Mass Spectrometry platform based on its proprietary SLIM technology, serving pharmaceutical R&D laboratories, academic researchers, and environmental testing organizations with superior-resolution separation of challenging biomolecules.
- Company typePrivate
- Founded2015
- HeadquartersChadds Ford, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mobilion Systems does
MOBILion Systems, Inc. is a privately-held analytical instrumentation company founded in 2015 and headquartered in Chadds Ford, Pennsylvania. The company develops and commercializes the MOBIE® platform, a High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) system built on its exclusively licensed proprietary SLIM (Structures for Lossless Ion Manipulation) technology. SLIM enables separations in milliseconds with near-100% ion utilization efficiency and resolutions that the company demonstrates as superior to conventional LC-MS and standard ion mobility methods for challenging analytes — including lipid isomers, peptide modifications, glycans, PFAS species, and lipid nanoparticles. The most recent technology addition is PAMAF™ (Preferential Fragment Ion Accumulation for MS/MS), an operating mode for the MOBIE platform that delivers a 300–2000% increase in fragment ion intensity for proteomics workflows.
The company's go-to-market is an enterprise field sales motion targeting pharmaceutical and biopharmaceutical R&D laboratories, academic research institutions, and government/environmental testing organizations through consultative selling with quote-based pricing and multi-year contracts. Revenue is generated primarily through hardware sales of MOBIE instruments, supplemented by recurring software, maintenance, training, and professional services. MOBILion has built a software integration ecosystem spanning Protein Metrics (Byos), Lipostar, Skyline, and TOFWERK, and has expanded into European markets through partnerships with BOKU Vienna, University of Duisburg-Essen, and direct European sales operations.
MOBILion has raised approximately $116.4M across disclosed funding rounds, including a $60M Series C in July 2021 led by D1 Capital Partners with participation from strategic investor Agilent Technologies. The company has achieved ISO 9001:2015 certification (2023), maintains active operations including product launches at HUPO 2025 and ongoing presence at ASMS through 2024, and has accumulated 100+ peer-reviewed publications citing its platform. Named customers and collaborators include Merck, Cedars Sinai, the EPA, the Michael J. Fox Foundation, and leading academic groups across Vanderbilt, UGA, Northeastern, and the University of Washington.
Mobilion Systems firmographics
Firmographics- Name
- Mobilion Systems
- Legal name
- MOBILion Systems, Inc.
- Website
- https://mobilionsystems.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MOBILion Systems develops and commercializes the MOBIE® High-Resolution Ion Mobility Mass Spectrometry platform based on its proprietary SLIM technology, serving pharmaceutical R&D laboratories, academic researchers, and environmental testing organizations with superior-resolution separation of challenging biomolecules.
- Ownership category
- akta.pro rank
Mobilion Systems industry classification
Industry- Product category
- Mass Spectrometry Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)
- akta.pro secondary industry
- Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)
Keywords
Where Mobilion Systems is headquartered
LocationHeadquarters
- HQ city
- Chadds Ford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mobilion Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- MOBIE Platform Sales: Sale of MOBIE high-resolution ion mobility mass spectrometry instruments to pharma, biopharma, and academic customers for analytical characterization workflows.
- Software and Services: Ongoing software solutions, maintenance, and professional services related to the MOBIE platform, including integration with software partners like Protein Metrics (Byos) and Lipostar.
- Professional Services: Training, certification, and professional services for customers engaging with the MOBIE platform and HRIM technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise instruments and services - quote-based pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Mobilion Systems product offering
Product offeringCore offering
MOBILion Systems designs, manufactures, and commercializes the MOBIE high-resolution ion mobility mass spectrometry (HRIM-MS) instrument platform, powered by its proprietary SLIM (Structures for Lossless Ion Manipulation) technology. The platform identifies and characterizes challenging biomolecules (lipids, peptides, glycans, PFAS, proteins) that conventional LC-MS instruments fail to resolve, and is sold to pharmaceutical R&D labs, biopharma companies, and academic research institutions for biotherapeutic characterization, biomarker discovery, and advanced analytical workflows.
Product overview
Mobilion Systems offers a unified product portfolio centered on the MOBIE® platform—a high-resolution ion mobility mass spectrometry (HRIM-MS) system based on proprietary SLIM (Structures for Lossless Ion Manipulation) technology. The MOBIE platform serves as the core product, enabling superior resolution separation of challenging molecules that traditional LC-MS cannot detect. Recent additions include PAMAF™ technology, a proprietary operating mode that dramatically enhances fragment ion intensity for proteomics workflows. The platform addresses multiple analytical workflows including targeted lipidomics, peptide characterization, glycan analysis, PFAS analysis, and lipid nanoparticle analysis, serving markets in biopharmaceutical development, biomarker discovery, cell and gene therapy, food and environmental testing, and therapeutic characterization.
Differentiator
Problem solved
Functional benefit
Brands
- MOBIE: High-resolution ion mobility mass spectrometry (HRIM-MS) platform for separating and identifying challenging molecules with superior resolution, rapid and reproducible results, faster method development, and simple method transfer.
- PAMAF
- SLIM
Products and services
- MOBIE® Platform High-resolution ion mobility mass spectrometry (HRIM-MS) instrument platform based on proprietary SLIM technology, providing superior resolution separation for identifying challenging molecules that other instruments fail to detect. Sold to pharmaceutical, biopharmaceutical, and academic customers for analytical characterization workflows including lipidomics, peptide characterization, glycan analysis, PFAS analysis, and lipid nanoparticle analysis.
- PAMAF™ Technology Proprietary operating mode for the MOBIE platform delivering a 300-2000% increase in fragment ion intensity and dramatically improving protein and PTM detection from small samples, specifically targeting proteomics research applications with enhanced sensitivity and throughput.
Quantifiable outcome
- 300-2000% increase in fragment ion intensity with PAMAF technology
- +4 more outcomes
Companies that use Mobilion Systems
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Mobilion Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
Feature7 records
Mobilion Systems partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered strategic, core and minor.
- TOFWERK AGstrategicLicense agreement enabling TOFWERK AG to expand applications of SLIM separation technology, extending the reach of MOBILion's core technology into additional markets.
- Protein MetricscoreIntegration partnership to combine Byos Software Suite with High-Resolution Ion Mobility Mass Spectrometry to accelerate biotherapeutic characterization workflows.
- Complex Carbohydrate Research Center at University of GeorgiastrategicPartnership for COVID-19 glycan analysis to better understand SARS-CoV-2 spike protein glycoproteins, potentially accelerating vaccine development.
- EPA (Environmental Protection Agency)strategicJoint research collaboration for PFAS analysis using MOBILion's HRIM technology to address environmental contamination challenges.
- Rilas TechnologiesminorPartnership to expand analytical offering with High Resolution Ion Mobility, integrating MOBILion technology into Rilas' analytical services.
- BOKU ViennastrategicPartnership to introduce High-Resolution Ion Mobility technology in Europe, expanding MOBILion's European market presence.
- Queen's University BelfastminorCollaboration to advance food safety using MOBILion's HRIM technology for enhanced analytical capabilities.
- University of Duisburg-EssenstrategicPartnership with leading researcher to advance metabolomics research and discovery using MOBILion's SLIM-based technology.
- Vanderbilt UniversityminorAcademic collaboration for characterization of previously unresolved lipids presented at ASMS 2022.
- Northeastern UniversityminorFirst application of native protein analysis using a commercial SLIM device collaboration presented at ASMS 2022.
- University of WashingtonminorResearch collaboration on precision, accuracy, and HRIM technology presented at ASMS 2022.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Mobilion Systems competitors and assessment
Company assessmentDirect peers
- 908 Devices: 908 Devices develops point-of-need mass spectrometry and chemical detection instruments for life sciences, safety, and applied markets. Both companies target novel MS architectures for specialized analytical use cases in pharma and adjacent markets, making 908 Devices a closely comparable peer in scale and technology posture.
- Excellims Corporation: Excellims develops ion mobility mass spectrometry instruments for pharmaceutical, security, and research applications. As a smaller-scale direct ion mobility MS peer, Excellims targets overlapping analytical use cases and customer types.
- MassTech Inc. MassTech (Applied Spectra) develops elemental and mass spectrometry instrumentation including ICP-MS and laser ablation systems. While more focused on elemental analysis, it competes in adjacent analytical instrument categories sold to similar industrial and research customers.
Broad incumbents
- Bruker: Bruker is a major analytical instrument vendor whose timsTOF trapped ion mobility mass spectrometry platform competes directly with MOBILion's HRIM in proteomics and biopharma workflows. As an incumbent with a competing ion mobility product, Bruker is the most analogous large-player peer.
- Agilent Technologies: Agilent is a global mass spectrometry leader and an existing MOBILion investor. Agilent's mass spec portfolio (including ICP-MS and LC-MS) overlaps with MOBIE's customer base in pharma R&D, environmental testing, and academic research, making it both a peer and a strategic stakeholder.
- Thermo Fisher Scientific: Thermo Fisher is the dominant mass spectrometry incumbent through its Orbitrap and TSQ product lines, serving pharma R&D, proteomics, and biomarker discovery — the same core markets MOBILion targets. It defines the competitive ceiling for MOBIE.
- Waters Corporation: Waters is a leading analytical instrument vendor specializing in LC and mass spectrometry for pharma, biomedical, and academic markets. Its mass spec and chromatography offerings serve the same pharma R&D and academic customers as MOBILion's MOBIE platform.
- SCIEX: SCIEX (part of Danaher) develops mass spectrometry and LC-MS/MS systems with strong positions in pharma R&D, biomarker discovery, and clinical research. Its Echo MS and ZenoTOF platforms compete with MOBIE in biotherapeutic characterization workflows.
Emerging players
- Owlstone Medical: Owlstone Medical commercializes FAIMS-based ion mobility technology for breath-based disease detection. As a fellow ion-mobility-platform company with a different application focus (clinical diagnostics), it represents a partial-overlap emerging peer in the broader ion mobility landscape.
Others
- Protein Metrics: Protein Metrics provides biotherapeutic characterization software (Byos) and is a current MOBILion integration partner. While not a direct competitor, Protein Metrics sits in the same biopharma analytical ecosystem and represents an ecosystem enabler rather than a competitor.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
Mobilion Systems social profiles
Digital presenceMobilion Systems compliance and trust
Trust signalCompliance2 records
Mobilion Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mobilion Systems leadership team
Management profileNumber of profiles
Profiles2 records
Mobilion Systems funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mobilion Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mobilion Systems
What does Mobilion Systems do?
MOBILion Systems designs, manufactures, and commercializes the MOBIE high-resolution ion mobility mass spectrometry (HRIM-MS) instrument platform, powered by its proprietary SLIM (Structures for Lossless Ion Manipulation) technology. The platform identifies and characterizes challenging biomolecules (lipids, peptides, glycans, PFAS, proteins) that conventional LC-MS instruments fail to resolve, and is sold to pharmaceutical R&D labs, biopharma companies, and academic research institutions for biotherapeutic characterization, biomarker discovery, and advanced analytical workflows.
Is Mobilion Systems a public or private company?
Mobilion Systems is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mobilion Systems founded?
Mobilion Systems was founded in 2015. It employs 51 to 100 people.
Where is Mobilion Systems based?
Mobilion Systems is headquartered in Chadds Ford, United States, in the North America region.
How does Mobilion Systems make money?
Three revenue lines are on record. MOBIE Platform Sales are the primary driver. The others are software and Services and professional Services.
Who are Mobilion Systems's main competitors?
Direct peers on record are 908 Devices, Excellims Corporation and MassTech Inc.. Broad incumbents are Bruker, Agilent Technologies, Thermo Fisher Scientific, Waters Corporation and SCIEX. Owlstone Medical is listed as an emerging player. Protein Metrics is listed as an others.
Does Mobilion Systems have an API?
No public API is recorded for Mobilion Systems.
What industry is Mobilion Systems in?
Mobilion Systems's product category is Mass Spectrometry Instrumentation. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments, with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.